Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>There are 24 adds and 14 deletes for the Hang Seng Composite Index (HSCI) at the September rebalance to take the number of index constituents up to 518.</li>
<li>19 of the 24 HSCI inclusions will be added to Southbound Stock Connect, while 12 of the 14 HSCI deletions will be removed from Southbound Stock Connect.</li>
<li>Five of the HSCI constituents could be removed from Southbound Stock Connect only since the average market cap over the last year is less than HK$5bn.</li>
</ul>


There are 24 adds and 14 deletes for the Hang Seng Composite Index (HSCI) at the September rebalance to take the number of index constituents up to 518.
19 of the 24 HSCI inclusions will be added to Southbound Stock Connect, while 12 of the 14 HSCI deletions will be removed from Southbound Stock Connect.
Five of the HSCI constituents could be removed from Southbound Stock Connect only since the average market cap over the last year is less than HK$5bn.


HSCI Index Rebalance: 24 Adds, 14 Deletes & Changes to Stock Connect

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Aug 5th based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Town Health International Medical (3886 HK), Neuedu (9616 HK), Sirnaomics-B (2257 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Aia (1299 HK), Tencent (700 HK), Great Wall Motor (2333 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Aug 5th based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Town Health International Medical (3886 HK), Neuedu (9616 HK), Sirnaomics-B (2257 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Aia (1299 HK), Tencent (700 HK), Great Wall Motor (2333 HK).


Hong Kong Buybacks: Town Health, Neuedu, Sirnaomics

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Jul 29th based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Great Wall Motor (2333 HK), Aia (1299 HK), Pop Mart (9992 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Aia (1299 HK), Great Wall Motor (2333 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Jul 29th based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Great Wall Motor (2333 HK), Aia (1299 HK), Pop Mart (9992 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Aia (1299 HK), Great Wall Motor (2333 HK).


Hong Kong Buybacks: Great Wall Motor, AIA, Pop Mart

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Jul 22nd based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were Aia (1299 HK), Pop Mart (9992 HK), Great Wall Motor (2333 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Aia (1299 HK), Great Wall Motor (2333 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Jul 22nd based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Aia (1299 HK), Pop Mart (9992 HK), Great Wall Motor (2333 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Aia (1299 HK), Great Wall Motor (2333 HK).


Hong Kong Buybacks: AIA, Pop Mart, Great Wall Motor

<ul>
<li>We see 28 potential inclusions to the HSCI in September, plus another 9 stocks that are close to the inclusion cutoff. Some stocks are already a part of Stock Connect.</li>
<li>There could be 22 deletions from the index on market cap, liquidity and prolonged suspension. Most of the deletions would be moved to the 'sell-only' Southbound Stock Connect list.</li>
<li>Some of the stocks that remain in the HSCI could move to the 'sell-only' Southbound Stock Connect list since their average market cap drops below HKD 5bn.</li>
</ul>


We see 28 potential inclusions to the HSCI in September, plus another 9 stocks that are close to the inclusion cutoff. Some stocks are already a part of Stock Connect.
There could be 22 deletions from the index on market cap, liquidity and prolonged suspension. Most of the deletions would be moved to the 'sell-only' Southbound Stock Connect list.
Some of the stocks that remain in the HSCI could move to the 'sell-only' Southbound Stock Connect list since their average market cap drops below HKD 5bn.


HSCI Index Rebalance and Stock Connect: Potential Changes in September

United States

Atara Biotherapeutics Inc. provides health care services. The Company offers research and development treatment solutions for cancer, kidney disease, and other illnesses.

Cidara Therapeutics, Inc. operates as a bio-pharmaceutical company. The Company focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Cidara Therapeutics serves customers in the United States.

Matinas BioPharma Holdings, Inc. operates as a clinical-stage biopharmaceutical company focused on identifying and developing effective anti-fungal and anti-bacterial therapeutics for the treatment of serious or life threatening infections.

Fortress Biotech, Inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. The Company will provide funding and management services to each of the Fortress Companies, and will seek licensing, partnerships, joint ventures and/or public and and private financing for research and development support.

Bioxcel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical development company. The Company utilizes big data, machine learning, and artificial intelligence to identify the next wave of medicines across neuroscience, immuno-oncology, and related diseases. BioXcel Therapeutics serves customers in the State of Connecticut.

Homology Medicines, Inc. operates as a genetic medicines company. The Company offers a platform to utilize human hematopoietic stem cell derived adeno-associated virus vectors to treat a range of disease-causing mutations through gene correction, insertion, and knockout. Homology Medicines serves patients in the United States.

Kezar Life Sciences, Inc. operates as a bio-technology company. The Company discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. Kezar Life Sciences serves healthcare sectors in the State of California.

Magenta Therapeutics, Inc. operates as a bio-technology company. The Company develops medicines, molecules, and cell therapy to transform patient preparation, stem cell expansion, and stem cell harvesting, as well as reduces post-transplant complications. Magenta Therapeutics serves patients in the State of Massachusetts.

NextCure, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing next generation immunomedicines for cancer and other diseases. NextCure serves health care industry.

Allakos Inc. operates as a clinical stage bio-technology company. The Company discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory, and proliferative diseases. Allakos serves customers in the United States.

Orthocell Ltd is a biotherapeutic technology development company seeking to address unmet clinical needs within the global orthopaedics sector. The Company's core focus is biological therapies for tendon and ligament tissue repair and regeneration.

AnGes MG, Inc. develops gene-therapy drugs that use Hepatocyte Growth Factor (HGF) for myocardial infarction and arteriosclerosis patients.  The Company also develops nucleic acid drug (decoy oligo) for patients with asthma, allergy, and rheumatism.  AnGes MG develops vectors (a carrier used to introduce a foreign gene into a host cell) which help study and analyze genetic functions.

Uni-Bio Science Group Limited is a bio-science related business with focus on the research, development and commercialization of biopharmaceuticals through recombinant DNA and other technologies.

Zenotech Laboratories Limited develops and manufactures generic biopharmaceuticals.  The Company also develops oncology and neurology drugs.

Allied Biotech Corp manufactures carotenoid formulations for food, supplement and feed industries. Products include beta-carotene, beta-apo-8-carotenal, coenzyme Q10 and lycopene.

Genomics BioSci & Tech Co., Ltd. provides complete and professional antibody production services, multiple immune animal systems, and complete antibody production consulting services. The Company offers DNA sequencing, primer synthesis, genetic function analysis, gene mutation analysis, and biological information integration.

Taiwan Advance Bio-Pharmaceutical Inc researches and develops IVD, antibiotic preparation, umbilical cord blood stem cell, other medical equipments. The company also provides drug testing services and biotechnology services.

Naturalendo Tech Co., Ltd. specializes in bio-sciences, herbs, and endocrinology.  The Company also develops, manufactures, and sells health care products such as natural medicine, health food, cosmetic material, and transdermal drug delivery system.

Seoulin Bioscience Co., Ltd. develops and provides biotechnology related products.  The Company's main products include DNA chip scanner and diagnostic DNA kit. Seoulin also operates various research.

Innovative Pharmaceutical Biotech Limited is a pharmaceutical company. The Company distributes gene-testing services, bio-industrial products and provides health care management services.

Sirnaomics Ltd. operates as a clinical-stage RNA therapeutics biopharmaceutical company. The Company's products includes oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. Sirnaomics conducts businesses in USA and China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sirnaomics (2257 HK)

HSCI Index Rebalance: 24 Adds, 14 Deletes & Changes to Stock Connect

There are 24 adds and 14 deletes for the HSCI at the September rebalance. 19 stocks will be added to Stock Connect and 12 will be removed. Some of...

Brian Freitas

Hong Kong Buybacks: Town Health, Neuedu, Sirnaomics

Past 7 day buybacks in HK market were 92.7% lower wow. The top 3 companies in terms of buybacks were Town Health International Medical (3886 HK),...

Ke Yan, CFA, FRM

Hong Kong Buybacks: Great Wall Motor, AIA, Pop Mart

We highlight the top 3 companies that repurchased the most shares from the HK market were Great Wall Motor (2333 HK), Aia (1299 HK), Pop Mart (9992...

Ke Yan, CFA, FRM

Hong Kong Buybacks: AIA, Pop Mart, Great Wall Motor

We highlight the top 3 companies that repurchased the most shares from HK market in the past 7 days were Aia (1299 HK), Pop Mart (9992 HK), Great...

Ke Yan, CFA, FRM

HSCI Index Rebalance and Stock Connect: Potential Changes in September

We see 28 potential adds and 9 close adds for the HSCI in September. There are 22 potential deletes on market cap, liquidity and prolonged...

Brian Freitas

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)